FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status
FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status
复制标题
DOI：
10.1016/j.radonc.2012.04.022
复制
发表时间：
2012-07-01
影响因子：
5.7
通讯作者：
la Fougere, Christian
中科院分区：
文献类型：
--
作者：
Niyazi, Maximilian;Schnell, Oliver;la Fougere, Christian
背景与目的：本研究的目的是评估根据EORTC/NCIC试验新诊断的胶质母细胞瘤患者在放化疗联合治疗后，由[F-18]FET-PET成像确定的复发模式的预测因素。材料与方法：回顾性分析79例新诊断的GBM患者放疗加替莫唑胺（75 mg/m(2)/d）后辅助循环替莫唑胺（150 ~ 200 mg/m(2)）治疗（5/28天）。复发模式通过正电子发射断层扫描与[F-18]场效应晶体管和额外的MRI评估；评估54例患者MGMT甲基化状态。结果：49.4%的患者有野内复发，12.6%的患者有野外复发，3.8%的患者有野边缘复发，34.2%的患者在随访期间（中位595天）没有复发。考虑到本研究纳入的所有患者，41.5%（12/29）的MGMT甲基化人群没有复发，37.9%（11/29）有场内复发，20.7%（6/29）有场外/边缘复发，而28.0%（7/25）的MGMT未甲基化人群没有复发，64.0%（16/25）有场内复发，8.0%（2/25）有场外/边缘复发（p = 0.15）。结论：胶质母细胞瘤患者在接受替莫唑胺联合或辅助放疗后，[(18)]FET-PET测定的模式似乎与MGMT甲基化状态有关。2012爱思唯尔爱尔兰有限公司版权所有。放射治疗与肿瘤学104 (2012)78-82
Background and purpose: The aim of the present study was to evaluate factors predicting the recurrence pattern determined by [F-18]FET-PET imaging in patients with newly diagnosed glioblastoma after combined radio-chemotherapy treated according to the EORTC/NCIC trial.Material and methods: Seventy-nine patients with newly diagnosed GBM treated with radiotherapy plus temozolomide (75 mg/m(2)/d) followed by adjuvant cyclic (5/28 days) temozolomide (150-200 mg/m(2)) were retrospectively analysed. Recurrence patterns were assessed by means of positron-emission-tomography with [F-18]FET and additional MRI; in 54 patients MGMT methylation status was evaluated.Results: Whilst 49.4% of the patients had an in-field recurrence, 12.6% an ex-field recurrence and 3.8% a recurrence at the field margin, 34.2% of the patients did not relapse during follow-up (median 595 days). Considering all patients included in this study, 41.5% (12/29) of the MGMT methylated population had no relapse, 37.9% (11/29) had an in-field-recurrence and 20.7% (6/29) an ex-field/marginal recurrence, whilst 28.0% (7/25) of the MGMT unmethylated population had no relapse, 64.0% (16/25) had an in-field-recurrence and 8.0% (2/25) an ex-field/marginal recurrence (p = 0.15).Conclusions: After the administration of temozolomide concomitant with and adjuvant to radiotherapy in patients with glioblastoma, the pattern determined by [(18)]FET-PET seems to be associated with MGMT methylation status. (C) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 104 (2012) 78-82